As global markets experience mixed performances, with the U.S. indices reaching record highs and Asian markets showing varied results, investors are increasingly turning their attention to potential opportunities in Asia. In this environment, identifying undervalued stocks can be a strategic move for those looking to capitalize on market inefficiencies and economic developments across the region.
|
Name |
Current Price |
Fair Value (Est) |
Discount (Est) |
|
Wenzhou Yihua Connector (SZSE:002897) |
CN¥37.49 |
CN¥74.86 |
49.9% |
|
T’Way Air (KOSE:A091810) |
₩2010.00 |
₩3982.45 |
49.5% |
|
Taiyo Yuden (TSE:6976) |
¥2573.00 |
¥5104.72 |
49.6% |
|
Shanghai Conant Optical (SEHK:2276) |
HK$37.15 |
HK$73.81 |
49.7% |
|
Serko (NZSE:SKO) |
NZ$3.16 |
NZ$6.27 |
49.6% |
|
Lai Yih Footwear (TWSE:6890) |
NT$287.50 |
NT$571.27 |
49.7% |
|
HL Holdings (KOSE:A060980) |
₩41150.00 |
₩81496.10 |
49.5% |
|
Hibino (TSE:2469) |
¥2360.00 |
¥4702.31 |
49.8% |
|
Darbond Technology (SHSE:688035) |
CN¥39.35 |
CN¥78.37 |
49.8% |
|
APAC Realty (SGX:CLN) |
SGD0.475 |
SGD0.95 |
49.8% |
Let’s uncover some gems from our specialized screener.
Overview: China National Software & Service Company Limited operates as a software company in China with a market cap of CN¥42.51 billion.
Operations: The company’s revenue segment is comprised of its Software Service Business, generating CN¥5.14 billion.
Estimated Discount To Fair Value: 10.4%
China National Software & Service is trading at approximately 10.4% below its estimated fair value of CN¥50.62, with a current price of CN¥45.36, suggesting potential undervaluation based on cash flows. Despite reporting a net loss of CN¥80.62 million for Q1 2025, the company is forecasted to achieve profitability within three years and expects revenue growth at 15.7% annually, surpassing the Chinese market average growth rate of 12.4%.
Overview: Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. operates in the biotechnology sector, focusing on the production of bio-based materials and ingredients, with a market cap of CN¥9.11 billion.
Operations: Revenue segments for the company are not provided in the text.
Estimated Discount To Fair Value: 12.6%
Shandong Bailong Chuangyuan Bio-Tech is trading at CN¥21.68, below its estimated fair value of CN¥24.8, indicating potential undervaluation based on cash flows. The company reported Q1 2025 revenue of CN¥313.3 million, up from CN¥252.11 million the previous year, with net income rising to CN¥81.42 million from CN¥53.54 million. Despite a volatile share price and low dividend coverage by free cash flow, revenue is forecasted to grow faster than the market at 20.1% annually.
